1
|
Marks DK, Budhathoki N, Kucharczyk J, Fa’ak F, D’Abreo N, Kwa M, Plasilova M, Dhage S, Soe PP, Becker D, Hindenburg A, Lee J, Winner M, Okpara C, Daly A, Shah D, Ramdhanny A, Meyers M, Oratz R, Speyer J, Novik Y, Schnabel F, Jones SA, Adams S. OUP accepted manuscript. Oncologist 2022; 27:89-96. [PMID: 35641208 PMCID: PMC8895753 DOI: 10.1093/oncolo/oyab042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/26/2021] [Accepted: 10/28/2021] [Indexed: 11/18/2022] Open
Abstract
Purpose Provide real-world data regarding the risk for SARS-CoV-2 infection and mortality in breast cancer (BC) patients on active cancer treatment. Methods Clinical data were abstracted from the 3778 BC patients seen at a multisite cancer center in New York between February 1, 2020 and May 1, 2020, including patient demographics, tumor histology, cancer treatment, and SARS-CoV-2 testing results. Incidence of SARS-CoV-2 infection by treatment type (chemotherapy [CT] vs endocrine and/or HER2 directed therapy [E/H]) was compared by Inverse Probability of Treatment Weighting. In those diagnosed with SARS-CoV-2 infection, Mann–Whitney test was used to a assess risk factors for severe disease and mortality. Results Three thousand sixty-two patients met study inclusion criteria with 641 patients tested for SARS-COV-2 by RT-PCR or serology. Overall, 64 patients (2.1%) were diagnosed with SARS-CoV-2 infection by either serology, RT-PCR, or documented clinical diagnosis. Comparing matched patients who received chemotherapy (n = 379) with those who received non-cytotoxic therapies (n = 2343) the incidence of SARS-CoV-2 did not differ between treatment groups (weighted risk; 3.5% CT vs 2.7% E/H, P = .523). Twenty-seven patients (0.9%) expired over follow-up, with 10 deaths attributed to SARS-CoV-2 infection. Chemotherapy was not associated with increased risk for death following SARS-CoV-2 infection (weighted risk; 0.7% CT vs 0.1% E/H, P = .246). Advanced disease (stage IV), age, BMI, and Charlson’s Comorbidity Index score were associated with increased mortality following SARS-CoV-2 infection (P ≤ .05). Conclusion BC treatment, including chemotherapy, can be safely administered in the context of enhanced infectious precautions, and should not be withheld particularly when given for curative intent.
Collapse
Affiliation(s)
- Douglas K Marks
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Long Island School of Medicine, Mineola, NY, USA
- Corresponding author: Douglas K. Marks, Department of Medicine, NYU Long Island School of Medicine, 120 Mineola Blvd, Suite 500 Mineola, NY 11501, USA.
| | | | | | - Faisal Fa’ak
- NYU Langone Hospital-Long Island, Mineola, NY, USA
| | - Nina D’Abreo
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Long Island School of Medicine, Mineola, NY, USA
| | - Maryann Kwa
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Magdalena Plasilova
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Surgery, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Shubhada Dhage
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Surgery, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Phyu Phyu Soe
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
| | - Daniel Becker
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
| | - Alexander Hindenburg
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Long Island School of Medicine, Mineola, NY, USA
| | - Johanna Lee
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
| | - Megan Winner
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Surgery, NYU Long Island School of Medicine, Mineola, NY,USA
| | | | - Alison Daly
- NYU Langone Hospital-Long Island, Mineola, NY, USA
| | - Darshi Shah
- NYU Langone Hospital-Long Island, Mineola, NY, USA
| | | | - Marleen Meyers
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Ruth Oratz
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - James Speyer
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Yelena Novik
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Freya Schnabel
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Surgery, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Simon A Jones
- Department of Population Health, NYU Grossman School of Medicine, Manhattan, NY, USA
| | - Sylvia Adams
- Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA
- Department of Medicine, NYU Grossman School of Medicine, Manhattan, NY, USA
| |
Collapse
|